#AstraZeneca, #Canada; #PotentialSideEffcts; #HealthCanada
Ontario/Canadian-Media: The first confirmed of rare but potentially fatal blood clotting had been reported by the Quebec's Ministry of Health and Social Services in Canada in connection with the AstraZeneca-Oxford COVID-19 vaccine after a female experienced an adverse event known as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
AstraZeneca Vaccine. Image credit: Wikimedia Commons
Quebec Health Minister Christian Dubé said yesterday that the woman in question was immediately taken care of and is doing fine.
Canada’s National Advisory Committee on Immunization has said that VIPIT occurs at a rate of about one in 100,000 people vaccinated, with a mortality rate of about 40 per cent, although more research is needed and that risk is reduced if treated early enough.
Concerns about vaccine side effects began in mid-March, following dozens of reports of blood clotting after inoculations, prompting several nearly 20 countries to halt the rollout of the AstraZeneca vaccine.
Earlier on Tuesday the federal department said in a statement that the first reported case of blood clotting will be included in Health Canada’s study of the link between the AstraZeneca vaccine and the deadly side effect.
Health Minister Patty Hajdu also said Canadian health regulators will not hesitate to change the terms of the AstraZeneca coronavirus vaccine license if additional safety issues emerge.
"All vaccines approved for use in Canada undergo routine and scrutinous attention. All adverse effects are reported through Health Canada and Health Canada monitors that data closely and will not hesitate to change its licensing for use in Canada should there be any risk to Canadians," Hajdu said during a Question Period session on Tuesday.
Health Canada has already paused inoculating Canadians under the age of 55 with the AstraZeneca vaccine following a recommendation from Canada’s National Advisory Committee on Immunizations (NACI).
A disclaimer has been issued by the Canadian health regulators regarding blood clots that may potentially form in individuals who receive an AstraZeneca shot, but have not officially listed it as an official side effect.